DE69511860D1 - Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine - Google Patents
Modifizierung von clostridium-toxinen und ihre anwendung als transport proteineInfo
- Publication number
- DE69511860D1 DE69511860D1 DE69511860T DE69511860T DE69511860D1 DE 69511860 D1 DE69511860 D1 DE 69511860D1 DE 69511860 T DE69511860 T DE 69511860T DE 69511860 T DE69511860 T DE 69511860T DE 69511860 D1 DE69511860 D1 DE 69511860D1
- Authority
- DE
- Germany
- Prior art keywords
- toxines
- clostridium
- modification
- transport proteins
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9410870A GB9410870D0 (en) | 1994-05-31 | 1994-05-31 | Modification of botulinum toxins for use as transport proteins |
GB9410871A GB9410871D0 (en) | 1994-05-31 | 1994-05-31 | Modification of tetanus toxin for use as a transport protein |
PCT/GB1995/001253 WO1995032738A1 (en) | 1994-05-31 | 1995-05-31 | Modification of clostridial toxins for use as transport proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69511860D1 true DE69511860D1 (de) | 1999-10-07 |
DE69511860T2 DE69511860T2 (de) | 2000-02-10 |
Family
ID=26304971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69511860T Expired - Fee Related DE69511860T2 (de) | 1994-05-31 | 1995-05-31 | Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine |
Country Status (9)
Country | Link |
---|---|
US (1) | US6203794B1 (de) |
EP (1) | EP0760681B1 (de) |
JP (1) | JP3523879B2 (de) |
AU (1) | AU695623B2 (de) |
CA (1) | CA2191754C (de) |
DE (1) | DE69511860T2 (de) |
DK (1) | DK0760681T3 (de) |
ES (1) | ES2138740T3 (de) |
WO (1) | WO1995032738A1 (de) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7227010B2 (en) | 1993-09-21 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
GB9524807D0 (en) * | 1995-12-05 | 1996-02-07 | Smithkline Beecham Plc | Novel compounds |
WO1997034620A1 (en) * | 1996-03-18 | 1997-09-25 | The Regents Of The University Of California | Peptide inhibitors of neurotransmitter secretion by neuronal cells |
US6444209B1 (en) | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
US5939070A (en) * | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
US6051239A (en) * | 1997-10-20 | 2000-04-18 | Thomas Jefferson University | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
EP1053014A4 (de) | 1998-01-26 | 2004-11-10 | Univ Massachusetts | BIOLOGISCH AKTIVES HÄMAGGLUTININ VOM TYP A i(STRIDIUM BOTULINUM) UNDVERFAHREN ZU SEINER VERWENDUNG |
DE19856052A1 (de) * | 1998-12-04 | 2000-06-08 | Deutsches Krebsforsch | Konjugat zur Anreicherung in neuronalen Zellen |
US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
US20040120891A1 (en) | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
US6776990B2 (en) * | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
WO2001018038A2 (en) * | 1999-08-20 | 2001-03-15 | Imperial College Innovations Limited | Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis |
EP2267010B1 (de) | 1999-08-25 | 2014-05-07 | Allergan, Inc. | Aktivierbare rekombinante Neurotoxine |
US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US6500436B2 (en) | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
AU2002228887B2 (en) * | 2000-11-06 | 2006-08-24 | United States Army Medical Research And Material Command | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
EP1386968A4 (de) * | 2001-04-09 | 2004-12-22 | Mitsubishi Pharma Corp | Einheit zur steuerung der genexpression und verwendung davon |
JP4707254B2 (ja) * | 2001-04-24 | 2011-06-22 | クミアイ化学工業株式会社 | 粒状組成物及びその製造方法 |
GB0112687D0 (en) * | 2001-05-24 | 2001-07-18 | Microbiological Res Authority | Pharmaceutical use of secreted bacterial effector proteins |
JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
NZ537120A (en) * | 2002-05-31 | 2008-07-31 | Univ Jefferson | Compositions and methods for transepithelial molecular transport |
US6776991B2 (en) * | 2002-06-26 | 2004-08-17 | Allergan, Inc. | Methods for treating priapism |
AU2003272800A1 (en) * | 2002-10-01 | 2004-04-23 | University Of Maryland | Methods for identifying inhibitors of botulinum neurotoxins |
US20040115727A1 (en) * | 2002-12-11 | 2004-06-17 | Allergan, Inc., A Corporation | Evolved clostridial toxins with altered protease specificity |
KR20050094817A (ko) * | 2002-12-20 | 2005-09-28 | 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. | 개선된 약제학적 보툴리늄 독소 조성물 |
JP2007070225A (ja) * | 2003-07-25 | 2007-03-22 | Yukako Fujinaga | クロストリジウム属菌由来成分を含む医薬製剤 |
US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
US7785606B2 (en) * | 2004-11-22 | 2010-08-31 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
CA2610103A1 (en) * | 2005-09-19 | 2007-03-19 | Allergan, Inc. | Clostridial toxin activatable clostridial toxins |
EP2505592A1 (de) | 2006-07-11 | 2012-10-03 | Allergan, Inc. | Modifizierte Clostridialtoxine mit erhöhter Translokationsfähigkeit und erweiterter Targeting-Aktivität |
AU2007272515B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
WO2009038770A2 (en) * | 2007-09-20 | 2009-03-26 | University Of Massachusetts Cvip | Detoxified recombinant botulinum neurotoxin |
WO2009131435A1 (en) * | 2008-04-23 | 2009-10-29 | Erasmus University Medical Center Rotterdam | Linker containing bungarotoxin and a binding peptide |
EP2364168A1 (de) | 2008-12-04 | 2011-09-14 | Botulinum Toxin Research Associates, Inc. | Verlängerte botulinustoxin-formulierung zur anwendung bei menschen oder säugetieren |
US8492109B2 (en) * | 2009-01-20 | 2013-07-23 | Trustees Of Tufts College | Methods for the delivery of toxins or enzymatically active portions thereof |
EP2218783A1 (de) | 2009-02-05 | 2010-08-18 | Merz Pharma GmbH & Co. KGaA | Neuartiges Verfahren zur Herstellung von Neurotoxinen |
US20120244188A1 (en) * | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
US20140377248A1 (en) | 2011-12-23 | 2014-12-25 | Merz Pharma Gmbh & Co. Kgaa | Method for the manufacturing of di-chain proteins for use in humans |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
JP6336970B2 (ja) | 2012-05-30 | 2018-06-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作されたボツリヌス神経毒素 |
US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
WO2014117148A1 (en) | 2013-01-28 | 2014-07-31 | New York University | Treatment methods using atoxic neurotoxin derivatives |
US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
US9975929B2 (en) | 2014-03-05 | 2018-05-22 | Merz Pharma Gmbh & Co. Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
WO2016094555A1 (en) | 2014-12-09 | 2016-06-16 | New York University | Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use |
ES2837699T3 (es) | 2014-12-19 | 2021-07-01 | Merz Pharma Gmbh & Co Kgaa | Medios y métodos para la determinación de la actividad biológica de BoNT/E en células |
DK3274364T3 (da) | 2015-03-26 | 2021-10-18 | Harvard College | Modificeret botulinumneurotoksin |
TW201718627A (zh) | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
US11078472B2 (en) | 2016-01-20 | 2021-08-03 | Merz Pharma Gmbh & Co., Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
CA3010146A1 (en) | 2016-03-02 | 2017-09-08 | Merz Pharma Gmbh & Co. Kgaa | Composition comprising botulinum toxin |
EP3504226A1 (de) | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Manipuliertes botulinumneurotoxin |
EP3290437A1 (de) | 2016-08-31 | 2018-03-07 | Merz Pharma GmbH & Co. KGaA | Neuartige rekombinante clostridienneurotoxine mit verkürzter wirkungsdauer |
AU2017326253B2 (en) | 2016-09-13 | 2021-10-21 | Allergan, Inc. | Stabilized non-protein clostridial toxin compositions |
EP3312193A1 (de) | 2016-10-19 | 2018-04-25 | Merz Pharma GmbH & Co. KGaA | Neuartige rekombinante botulinumneurotoxine mit beschleunigter wirkung |
DK3529616T3 (da) | 2016-10-20 | 2023-12-11 | Harvard College | In vitro- og cellebaserede assays til måling af aktiviteten af botulinum-neurotoksiner |
EP3333179A1 (de) | 2016-12-07 | 2018-06-13 | Merz Pharma GmbH & Co. KGaA | Neuartiges rekombinantes botulinumneurotoxin mit beschleunigtem wirkungseintritt |
EP3335719A1 (de) | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Neuartige rekombinante botulinumneurotoxine mit einer stabilisierten leichten kette |
US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
EP3649143B1 (de) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
EP3700919A1 (de) | 2017-10-26 | 2020-09-02 | Merz Pharma GmbH & Co. KGaA | Neuartige rekombinante botulinum-neurotoxine mit erhöhter wirkdauer |
US20200354706A1 (en) | 2017-11-22 | 2020-11-12 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
EP3823674A4 (de) | 2018-07-18 | 2022-12-28 | Manzanita Pharmaceuticals, Inc. | Konjugate zur abgabe eines krebsmittels an nervenzellen, verwendungsverfahren und verfahren zu deren herstellung |
WO2023105289A1 (en) | 2021-12-06 | 2023-06-15 | Dublin City University | Methods and compositions for the treatment of pain |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4594336A (en) * | 1982-09-28 | 1986-06-10 | Institut Pasteur | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application |
US4713240A (en) * | 1985-04-04 | 1987-12-15 | Research Corporation | Vaccines based on insoluble supports |
US5204097A (en) * | 1986-07-06 | 1993-04-20 | Yeda Research And Development Company Limited | Shiga toxin B chain polypeptides and vaccine thereto |
IL79346A0 (en) * | 1986-07-06 | 1986-10-31 | Yeda Res & Dev | Shiga vaccine |
US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
US5196193A (en) * | 1989-10-31 | 1993-03-23 | Ophidian Pharmaceuticals, Inc. | Antivenoms and methods for making antivenoms |
US5719267A (en) * | 1989-10-31 | 1998-02-17 | Ophidian Pharmaceuticals Inc. | Clostridial toxin disease therapy |
US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
US5599539A (en) * | 1989-10-31 | 1997-02-04 | Ophidian Pharmaceuticals, Inc. | Therapy for clostridial botulinum toxin |
US5601823A (en) * | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
CA2129899C (en) * | 1992-02-11 | 2011-01-04 | James J. Mond | Dual carrier immunogenic construct |
WO1994000481A1 (en) * | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Pharmaceutical composition containing botulinum b complex |
WO1994000487A1 (en) * | 1992-06-30 | 1994-01-06 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Peptide which produces protective immunity against tetanus |
GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5693476A (en) * | 1995-02-24 | 1997-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of screening for compounds capable of modulating vesicular release |
US5650280A (en) * | 1995-03-23 | 1997-07-22 | Incyte Pharmaceuticals, Inc. | Cellubrevin homolog |
US5721215A (en) * | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
US5965699A (en) * | 1996-11-06 | 1999-10-12 | The United States Of America As Represented By The Secretary Of The Army | Assay for the proteolytic activity of serotype a from clostridium botulinum |
US5955368A (en) * | 1998-04-06 | 1999-09-21 | Wisconsin Alumni Research Foundation | Expression system for clostridium species |
-
1995
- 1995-05-31 EP EP95921007A patent/EP0760681B1/de not_active Expired - Lifetime
- 1995-05-31 DK DK95921007T patent/DK0760681T3/da active
- 1995-05-31 AU AU26222/95A patent/AU695623B2/en not_active Ceased
- 1995-05-31 JP JP50052496A patent/JP3523879B2/ja not_active Expired - Fee Related
- 1995-05-31 CA CA002191754A patent/CA2191754C/en not_active Expired - Fee Related
- 1995-05-31 US US08/750,101 patent/US6203794B1/en not_active Expired - Fee Related
- 1995-05-31 ES ES95921007T patent/ES2138740T3/es not_active Expired - Lifetime
- 1995-05-31 WO PCT/GB1995/001253 patent/WO1995032738A1/en active IP Right Grant
- 1995-05-31 DE DE69511860T patent/DE69511860T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0760681A1 (de) | 1997-03-12 |
DE69511860T2 (de) | 2000-02-10 |
CA2191754C (en) | 2000-12-12 |
DK0760681T3 (da) | 2000-03-27 |
CA2191754A1 (en) | 1995-12-07 |
EP0760681B1 (de) | 1999-09-01 |
ES2138740T3 (es) | 2000-01-16 |
AU695623B2 (en) | 1998-08-20 |
JP3523879B2 (ja) | 2004-04-26 |
AU2622295A (en) | 1995-12-21 |
US6203794B1 (en) | 2001-03-20 |
JPH10500988A (ja) | 1998-01-27 |
WO1995032738A1 (en) | 1995-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69511860T2 (de) | Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine | |
ATE277895T1 (de) | 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren | |
DE69736664D1 (de) | Segmentierung und wiederzusammensetzung von minizellen | |
ATE321777T1 (de) | Ölkörper und damit assoziierte proteine als affinitätsmatrix | |
DE69325577T2 (de) | Mn-gen und protein | |
DE69322062T2 (de) | Emulsionspolymere und ihre verwendung in haarfestigungszubereitungen | |
DE69715635T2 (de) | Neue amidinoderivate und ihre anwendung als thrombin inhibitoren | |
DE896624T1 (de) | Weinrebe-blattroll-virus proteine und ihre verwendung | |
DE59708905D1 (de) | Injektionsformulierungen von avermectinen und milbemycinen | |
DE69825625D1 (de) | Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen | |
DE59812513D1 (de) | Verwendung von W/O-Emulsionen als Verdicker in kosmetischen und pharmazeutischen Zubereitungen | |
DE69716896D1 (de) | Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression | |
DE69816046D1 (de) | Zusammensetzung auf basis von hexanitrohexaazaisowurtizitan und hexanitrohexaazaisowurtizitan enthaltende sprengstoffzusammensetzung | |
DE69702554D1 (de) | Aminopeptidase GX und damit Hydrolysierungsverfahren von Proteine | |
DE69717677T2 (de) | Koproduktion von perfluormethylperfluorvinylether und perfluorethylperfluorvinylether | |
ATE233569T1 (de) | Verwendung von proteine als mittel gegen autoimmunekrankheiten | |
ATE242270T1 (de) | Stabilisierte proteine mit protease- inhibitorfunktion und varianten davon | |
DE986641T1 (de) | Proteine des blattrollvirus der weinrebe (type 2) und ihre verwendungen. | |
DE59708755D1 (de) | Verwendung von 3-Acylthiohexylestern als Aroma- und Riechstoffe | |
DE59809194D1 (de) | 8-Ocimenylester und ihre Verwendung als Riech- und Aromastoffe | |
DE59510203D1 (de) | Aminosäure-Derivate und ihre Verwendung als Schädlingsbekämpfungsmittel | |
FI955537A0 (fi) | Fibrinolyyttiset ja hyytymistä estävät proteiinit | |
DE69331597D1 (de) | Methoden und Verwendung von poly-L-lysine als Enzymschutzmittel | |
ATE218343T1 (de) | Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva | |
DE69839508D1 (de) | Chinolinmorphinan-derivate und ihre medizinische anwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |